Leon Hamrick, MD
Urology · Homewood, ALNPI 1871680785
Payments from drug & device makers
Across 192 payments — averaging $27.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$2K
- Sumitomo Pharma America, Inc.$1K
- Astellas Pharma US Inc$463
- Urovant Sciences Inc$304
- AbbVie$273
- Urogen Pharma, Inc.$173
- plus $1K from 34 others
What the payments were for
- Travel & lodging$1,09620%
- Food & beverage$3,76470%
- Education$4949%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 14 | $1,558 |
| Sumitomo Pharma America, Inc. | 58 | $1,178 |
| Astellas Pharma US Inc | 14 | $463 |
| Urovant Sciences Inc | 21 | $304 |
| AbbVie(2 entities) | 10 | $273 |
| Urogen Pharma, Inc. | 4 | $173 |
| Coloplast | 7 | $169 |
| Pfizer | 7 | $130 |
| Progenics Pharmaceuticals, Inc. | 4 | $86 |
| Tolmar Pharmaceuticals, Inc. | 3 | $72 |
| Myovant Sciences Inc. | 3 | $66 |
| Immunitybio, Inc. | 2 | $60 |
| Ferring Pharmaceuticals Inc. | 3 | $58 |
| Myriad Genetic Laboratories, Inc. | 2 | $53 |
| Tolmar, Inc. | 2 | $51 |
| Merck | 2 | $46 |
| Dendreon Pharmaceuticals LLC | 2 | $44 |
| Travere Therapeutics, Inc. | 8 | $42 |
| Hollister Incorporated | 2 | $41 |
| Novo Nordisk | 2 | $35 |
| Medtronic | 2 | $34 |
| Boston Scientific | 1 | $31 |
| 180 Medical, Inc. | 1 | $29 |
| Olympus America Inc. | 1 | $29 |
| Telix Pharmaceuticals | 1 | $27 |
| Provepharm Inc. | 1 | $26 |
| Axonics, Inc. | 2 | $26 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Cook Medical LLC | 1 | $23 |
| Blue Earth Diagnostics | 1 | $21 |
| Antares Pharma, Inc. | 1 | $21 |
| Sanofi | 1 | $21 |
| Neotract Inc. | 1 | $20 |
| Profound Medical Corp. | 1 | $19 |
| Cycle Pharmaceuticals Inc | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $14 |
| Ambu Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$1,074
- JELMYTO$122
How this compares
$5,353 in reported general payments places this provider in the 60th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 187 | $133,054 |
| MyrbetriqMirabegron | 112 | $74,582 |
| Tamsulosin Hcl | 805 | $11,591 |
| Dutasteride | 304 | $10,534 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 374 | $8,660 |
| Trospium Chloride | 136 | $8,619 |
| Trospium Chloride ErTrospium Chloride | 23 | $6,819 |
| Silodosin | 54 | $6,511 |
| Potassium Citrate ErPotassium Citrate | 66 | $4,496 |
| Solifenacin Succinate | 75 | $3,518 |
| Estradiol | 20 | $3,443 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $2,525 |
| Finasteride | 164 | $2,425 |
| NitrofurantoinNitrofurantoin Macrocrystal | 72 | $1,832 |
| Trimethoprim | 30 | $1,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $1,178 | $133,054187 claims |
| Astellas Pharma US IncMyrbetriq | $463 | $74,582112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 179 urology providers in Alabama.
Other urology in Homewood
- Vincent BivinsHomewood$1.3M
- Charles BuggHomewood$544K
- Brian ChristineHomewood$372K
- Austin LutzHomewood$367K
- Mark DeguentherHomewood$342K
- Paula RookisHomewood$174K
- Bryant PooleHomewood$123K
- Andrew StrangHomewood$91K
- Michael BrewerHomewood$77K
- Rachel EngelbergHomewood$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.